|
Age > 70 years
|
35 (36.8 %)
|
11 (39.3 %)
|
.25
|
|
≥1 comorbidity
|
46 (68.7 %)
|
24 (85.7 %)
|
.09
|
|
Total hip arthroplasty
|
40 (42.1 %)
|
10 (35.7 %)
|
.03
|
|
Type of infection (early/delayed/late)
|
20 (29.8 %)/18 (26.9 %)/29 (43.3 %)
|
11 (39.3 %)/7 (25 %)/10 (35.7 %)
|
.19
|
|
Fever
|
35 (36.8 %)
|
17 (60.7 %)
|
.45
|
|
CRP in mg/L, mean value ± SD
|
154.6 ± 121.9
|
207.2 ± 148.3
|
.09
|
|
S. agalactiae (group B streptococci)
|
27 (28.4 %)
|
10 (35.7 %)
|
.68
|
|
Antibiotic treatment prior to admission
|
18 (18.9 %)
|
8 (28.6 %)
|
.86
|
|
Sinus tract
|
15 (15.8 %)
|
3 (10.7 %)
|
.18
|
|
Concomitant bacteremia at the time of diagnosis
|
11 (16.4 %)
|
8 (28.6 %)
|
.18
|
|
DAIR
|
32 (33.7 %)
|
23 (82.1 %)
|
.002
|
|
Primary arthroplasty
|
53 (79.1 %)
|
20 (71.4 %)
|
.42
|
|
Hematogenous origin
|
10 (14.9 %)
|
8 (28.6 %)
|
.12
|
|
Rifampicin based combinations
|
44 (46.3 %)
|
8 (28.6 %)
|
.001
|
|
Rifampicin + levofloxacin
|
24 (25.2 %)
|
4 (14.3 %)
|
.04
|
